JP2021511362A5 - - Google Patents

Info

Publication number
JP2021511362A5
JP2021511362A5 JP2020540787A JP2020540787A JP2021511362A5 JP 2021511362 A5 JP2021511362 A5 JP 2021511362A5 JP 2020540787 A JP2020540787 A JP 2020540787A JP 2020540787 A JP2020540787 A JP 2020540787A JP 2021511362 A5 JP2021511362 A5 JP 2021511362A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
approximately
fusion protein
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020540787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511362A (ja
JP7345479B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015268 external-priority patent/WO2019148020A1/en
Publication of JP2021511362A publication Critical patent/JP2021511362A/ja
Publication of JP2021511362A5 publication Critical patent/JP2021511362A5/ja
Application granted granted Critical
Publication of JP7345479B2 publication Critical patent/JP7345479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020540787A 2018-01-26 2019-01-25 組成物及び使用方法 Active JP7345479B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862622704P 2018-01-26 2018-01-26
US62/622,704 2018-01-26
US201862697372P 2018-07-12 2018-07-12
US62/697,372 2018-07-12
PCT/US2019/015268 WO2019148020A1 (en) 2018-01-26 2019-01-25 Compositions and methods of use

Publications (3)

Publication Number Publication Date
JP2021511362A JP2021511362A (ja) 2021-05-06
JP2021511362A5 true JP2021511362A5 (cg-RX-API-DMAC10.html) 2022-02-01
JP7345479B2 JP7345479B2 (ja) 2023-09-15

Family

ID=65409540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540787A Active JP7345479B2 (ja) 2018-01-26 2019-01-25 組成物及び使用方法

Country Status (21)

Country Link
US (2) US12171805B2 (cg-RX-API-DMAC10.html)
EP (1) EP3743088B1 (cg-RX-API-DMAC10.html)
JP (1) JP7345479B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200125590A (cg-RX-API-DMAC10.html)
CN (1) CN112020365A (cg-RX-API-DMAC10.html)
AU (1) AU2019212703A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020015016A2 (cg-RX-API-DMAC10.html)
CA (1) CA3088763A1 (cg-RX-API-DMAC10.html)
DK (1) DK3743088T3 (cg-RX-API-DMAC10.html)
ES (1) ES2932861T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20221448T1 (cg-RX-API-DMAC10.html)
HU (1) HUE060435T2 (cg-RX-API-DMAC10.html)
IL (1) IL276135A (cg-RX-API-DMAC10.html)
LT (1) LT3743088T (cg-RX-API-DMAC10.html)
MX (1) MX2020007628A (cg-RX-API-DMAC10.html)
PL (1) PL3743088T3 (cg-RX-API-DMAC10.html)
PT (1) PT3743088T (cg-RX-API-DMAC10.html)
RS (1) RS63812B1 (cg-RX-API-DMAC10.html)
SI (1) SI3743088T1 (cg-RX-API-DMAC10.html)
TW (1) TWI835773B (cg-RX-API-DMAC10.html)
WO (1) WO2019148020A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
WO2020074957A1 (en) * 2018-10-12 2020-04-16 Sanotize Research And Development Corp. Gas-evolving compositions and container and delivery systems
CA3143633A1 (en) * 2019-07-26 2021-02-04 Matthew Kalo Dosing for prevention or treatment of graft versus host disease (gvhd) with il-22 fc fusion proteins
EP4106794A4 (en) * 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
EP4674865A3 (en) * 2021-03-09 2026-03-25 GI Innovation, Inc. Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
EP4792826A1 (en) * 2023-10-12 2026-08-19 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Ngf-fc fusion protein formulation and use thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4717717A (en) 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5705485A (en) 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP1107791B8 (en) 1998-09-04 2007-11-07 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
BR0012429A (pt) * 1999-07-15 2002-09-17 Genetics Inst Fórmulações para il-11
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060287234A1 (en) 2005-06-17 2006-12-21 Genentech, Inc. Wound healing
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20130121959A1 (en) * 2010-01-13 2013-05-16 Joseph R. Maxwell Il-22-fc and hepcidin activity
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
UY35460A (es) 2013-03-15 2014-10-31 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
PL2970422T3 (pl) * 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
KR102386735B1 (ko) * 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity

Similar Documents

Publication Publication Date Title
JP7544932B2 (ja) 抗体含有製剤
US20230047111A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
JP6199298B2 (ja) メグルミンによって安定化されたエタネルセプト製剤
JP7208302B2 (ja) 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
AU2022203741B2 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
JP2022526799A5 (cg-RX-API-DMAC10.html)
HRP20221448T1 (hr) Il-22 fc pripravci i postupci njihove primjene
JP2019509311A5 (cg-RX-API-DMAC10.html)
JP2023550203A5 (cg-RX-API-DMAC10.html)
JP2023513833A5 (cg-RX-API-DMAC10.html)
US11389515B2 (en) Method for mitigating heart disease
JP2020502132A (ja) 皮膚の繊維化を予防及び治療するための方法
WO2022242527A1 (zh) 一种单克隆抗体-细胞因子融合蛋白制剂
JP2025512832A5 (cg-RX-API-DMAC10.html)
WO2012144579A1 (ja) 溶液状抗体製剤
CN108210912A (zh) 一种使胰高血糖素、胰岛素恢复正常平衡的方法
US20230263856A1 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US11612637B2 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US20220288167A1 (en) A stable lyophilized formulation for hybrid fc fused g-csf
CN118078988A (zh) 包含靶向il-17a的抗体药物组合物
US20060263358A1 (en) Method for reducing sepsis or cardiogenic shock associated with myocardial injury
RU2024121587A (ru) ЖИДКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ СЛИТЫЙ БЕЛОК, ВКЛЮЧАЮЩИЙ α-ГАЛАКТОЗИДАЗУ A
JP2025502861A5 (cg-RX-API-DMAC10.html)